Linong Ji1, Dajin Zou2, Li Liu3, Lei Qian4, Zbigniew Kadziola5, Steven Babineaux6, He Na Zhang3, Robert Wood7. 1. Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. 2. Endocrinology Department, Affiliated Changhai Hospital to the 2nd Military Medical University, Shanghai, China. 3. Medical Division, Lilly Suzhou Pharmaceutical Co., Ltd, Shanghai, China. 4. Medical Division, Lilly Suzhou Pharmaceutical Co., Ltd, Shanghai, China. Electronic address: qian_lei_sh@lilly.com. 5. Eli Lilly and Co., Real World Analytics, Vienna, Austria. 6. Eli Lilly and Co., Indianapolis, IN, USA. 7. Adelphi Real World, Bollington, Cheshire, UK.
Abstract
AIMS: Association between body mass index (BMI) and glycemic control, comorbidities/complications, and health-related quality of life (HRQoL) was assessed in Chinese patients with type 2 diabetes mellitus (T2DM) enrolled in the Diabetes Disease Specific Programme. METHODS: Surveys of 200 physicians and 2052 patients with T2DM captured demographic, clinical, and HRQoL information. Adjusted and unadjusted analyses were conducted across 3 BMI groups; normal (18.5-<24.0, n=998), overweight (24.0-<28.0, n=822), and obese (≥28.0, n=212). RESULTS: There were no between group differences in the achievement of glycated hemoglobin (HbA1c) <7.0% (48mmol/mol); however, compared with the normal BMI group, more obese patients had an HbA1c >9.0% (75mmol/mol; 4.3% vs 10.2%, P=0.002). More obese patients compared with normal BMI patients had hypertension (48.6% vs 35.3%, P<0.001), dyslipidemia (35.4% vs 18.8%, P<0.001), or both hypertension and dyslipidemia (24.1% vs 13.9%, P<0.001). Patients in the obese group reported worse HRQoL and greater effects of diabetes on their daily living. CONCLUSIONS: Obesity in Chinese patients with T2DM results in poor glycemic control, more comorbidities, and worse HRQoL. Management of these patients should include efforts to reduce weight. Selection of weight-neutral or weight-reducing anti-diabetic medications maybe useful in these patients.
AIMS: Association between body mass index (BMI) and glycemic control, comorbidities/complications, and health-related quality of life (HRQoL) was assessed in Chinese patients with type 2 diabetes mellitus (T2DM) enrolled in the Diabetes Disease Specific Programme. METHODS: Surveys of 200 physicians and 2052 patients with T2DM captured demographic, clinical, and HRQoL information. Adjusted and unadjusted analyses were conducted across 3 BMI groups; normal (18.5-<24.0, n=998), overweight (24.0-<28.0, n=822), and obese (≥28.0, n=212). RESULTS: There were no between group differences in the achievement of glycated hemoglobin (HbA1c) <7.0% (48mmol/mol); however, compared with the normal BMI group, more obesepatients had an HbA1c >9.0% (75mmol/mol; 4.3% vs 10.2%, P=0.002). More obesepatients compared with normal BMI patients had hypertension (48.6% vs 35.3%, P<0.001), dyslipidemia (35.4% vs 18.8%, P<0.001), or both hypertension and dyslipidemia (24.1% vs 13.9%, P<0.001). Patients in the obese group reported worse HRQoL and greater effects of diabetes on their daily living. CONCLUSIONS: Obesity in Chinese patients with T2DM results in poor glycemic control, more comorbidities, and worse HRQoL. Management of these patients should include efforts to reduce weight. Selection of weight-neutral or weight-reducing anti-diabetic medications maybe useful in these patients.